華潤醫療(01515.HK)中期淨利1.99億元 同比增加84.97%
格隆匯8月25日丨華潤醫療(01515.HK)公佈，截至2021年6月30日止6個月，公司實現營業收入17.72億元人民幣，同比增加95.29%；母公司擁有人應占期內淨利1.99億元，同比增加84.97%；每股盈利0.16元。
集團實現綜合營業額及淨利潤增長，主要是由於我國新冠病毒疫情受到有效防控，因此報吿期內集團下屬成員醫院的業務恢復良好，報吿期內公司下屬成員醫院在業務量、收入和經營利潤方面均較去年同期有大幅提升，整體門急診人次及出院人次分別增長了50.5%和36.8%，成員醫院醫療業務收入則錄得同比增長39.8%。
截至2021年6月30日，集團在中國8個省、市共管理運營123家醫療機構。於報吿期內，集團成員醫院門診量和住院量分別約為473.9萬人次和12.8萬人次。
2021年下半年，公司將繼續堅持以醫療服務為主業，加強學科建設，佈局優勢專科，聚焦心血管、腦病、骨科、康復、消化和腫瘤等優勢專科，建設六大學科集羣，打造華潤醫療優勢學科品牌。亦將持續優化患者服務，完善患者服務體系，創造良好患者體驗，塑造行業標杆，形成易於推廣的標準化服務體系，樹立醫療服務品牌。在醫院運營方面，將形成品質控制與管理方面的完善體系，加強品質安全管理，對醫療服務的品質安全管理進行全流程管控；另一方面，還將持續深化醫院運營管理體系，提升運營效率，降低運營成本，提高服務效率。集團擇機獲取優質醫療資產，存量醫院視機擴張牀位規模，建設具有專科特色、地區領先的"強專科、大綜合"醫院。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
